Menu
Close
Primary links
Newsroom Home
Press Releases
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
Biosimilars
Collaborations
Events & Webcasts
Sign up for Alerts
All Press Releases
Login
All Press Releases
Filter by
<Any>
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
-Year
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Search
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
12/20/17 4:01 pm EST
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
12/18/17 4:01 pm EST
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference
12/7/17 4:01 pm EST
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/20/17 4:01 pm EST
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
10/30/17 4:01 pm EDT
Biogen Reports Quarterly Revenues of $3.1 Billion
10/24/17 6:59 am EDT
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
10/24/17 6:29 am EDT
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
9/26/17 4:01 pm EDT
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
9/6/17 4:01 pm EDT
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
7/25/17 6:30 am EDT
1
2
3
next ›
last »
Investor Relations Press Releases
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
12/20/17 4:01 pm EST
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
12/18/17 4:01 pm EST
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference
12/7/17 4:01 pm EST
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/20/17 4:01 pm EST
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
10/30/17 4:01 pm EDT
Biogen Reports Quarterly Revenues of $3.1 Billion
10/24/17 6:59 am EDT
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
10/24/17 6:29 am EDT
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
9/26/17 4:01 pm EDT
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
9/6/17 4:01 pm EDT
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
7/25/17 6:30 am EDT
1
2
3
next ›
last »
